Agenus President and COO Jennifer Buell resigns to lead subsidiary MiNK Therapeutics

AGENUS INC

Dr. Jennifer Buell resigned as President and COO effective December 31, 2021.
She becomes President and CEO of MiNK Therapeutics, a subsidiary of Agenus.
Buell will also serve on Agenus' Executive Council to advise on pipeline synergy.
No successor as President/COO announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jennifer Buell

President and Chief Operating Officer

AGEN · AGENUS INC

Effective: 2021-12-31
Filed: January 6, 2022, 6:59 PM ET

Effective December 31, 2021, Dr. Jennifer Buell resigned as Agenus Inc.’s (the “Company”) President and Chief Operating Officer to become the President and Chief Executive Officer of MiNK Therapeutics, Inc. (“MiNK”), a subsidiary of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Buell resigned as President and Chief Operating Officer at AGENUS INC.

Action: resigned
Role: President and Chief Operating Officer

Exact text from the filing

Effective December 31, 2021, Dr. Jennifer Buell resigned as Agenus Inc.’s (the “Company”) President and Chief Operating Officer to become the President and Chief Executive Officer of MiNK Therapeutics, Inc. (“MiNK”), a subsidiary of the Company.

View on SEC.gov

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001193125-22-003643

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.